2404
E. Aehle et al. / Phytochemistry 72 (2011) 2396–2405
to 0.9–1.7 mM (500 mgLꢀ1
) alone or in combination with
Acknowledgements
220 pM (60 ngLꢀ1
)
17b-estradiol. The assay consisted of
b-galactosidase from E. coli (Sigma) 450 pkat/well, o-nitrophenyl
b- -galactoside (Sigma) 2.3 mM, lignans, isoflavonoids, and
The German Federal Ministry of Education and Research BMBF,
InnoRegio program, financially supported work in Halle. Christoph
Schäfers, Fraunhofer Institute for Molecular Biology and Applied
Ecology, Schmallenberg, Germany, kindly provided the yeast cells.
D
17b-estradiol 35 pM–1.7 mM, MgCl2 1 mM, 2-mercaptoethanol
113 mM, dissolved in sodium phosphate buffer 100 mM, pH
7.3, total volume 100 ll in 96-well plates. After pre-incubation
References
at 37 °C for 1 h without substrate, absorbance was read 4 min
after substrate addition for 20 min at 414 nm. Enzyme activity
was calculated after calibration with o-nitrophenol in 96-well
plates. Most lignans did not inhibit the b-galactosidase assay,
or their inhibitory activity was weak and only visible in the
highest concentration in the assays (Table 1). Enterodiol, entero-
lactone, and S3 (1.5–1.7 mM) reduced b-galactosidase activity to
10%, 73%, and 87%, respectively, of control. Daidzein, genistein,
and 17b-estrogen did not interfere with the b-galactosidase
assay.
Adlercreutz, H., 2007. Lignans and human health. Crit. Rev. Clin. Lab. Sci. 44, 483–
525.
Adlercreutz, H., 2002. Phyto-oestrogens and cancer. Lancet Oncol. 3, 364–373.
Axelson, M., Sjoevall, J., Gustafsson, B., Setchell, K., 1982. Origin of lignans in
mammals and identification of a precursor from plants. Nature 298, 659–660.
Beresford, N., Routledge, E., Harris, C., Sumpter, J., 2000. Issues arising when
interpreting results from an in vitro assay for estrogenic activity. Toxicol. Appl.
Pharmacol. 162, 22–33.
Bovee, T.F.H., Thevis, M., Hamers, A.R.M., Peijnenburg, A.A.C.M., Nielen, M.W.F.,
Schoonen, W.G.E.J., 2010. SERMs and SARMs: detection of their activities with
yeast based bioassays. J. Steroid Biochem. Mol. Biol. 118, 85–92.
Brzozowski, A., Pike, A., Dauter, Z., Hubbard, R., Bonn, T., Engstrom, O., Ohman, L.,
Greene, G., Gustafsson, J., Carlquist, M., 1997. Molecular basis of agonism and
antagonism in the oestrogen receptor. Nature 389, 753–758.
4.5. Computational modelling
Carreau, C., Flouriot, G., Bennetau-Pelissero, C., Potier, M., 2008. Enterodiol and
enterolactone, two major diet-derived polyphenol metabolites have different
impact on ER alpha transcriptional activation in human breast cancer cells. J.
Steroid Biochem. Mol. Biol. 110, 176–185.
Case, D., Cheatham, T., Darden, T., Gohlke, H., Luo, R., Merz, K., Onufriev, A.,
Simmerling, C., Wang, B., Woods, R., 2005. The Amber biomolecular simulation
programs. J. Comput. Chem. 26, 1668–1688.
Davin, L.B., Lewis, N.G., 2003. An historical perspective on lignan biosynthesis:
Monolignol, allylphenol and hydroxycinnamic acid coupling and downstream
metabolism. Phytochem. Rev. 2, 257–288.
Dhooge, W., Arijs, K., D’Haese, I., Stuyvaert, S., Versonnen, B., Janssen, C., Verstraete,
W., Comhaire, F., 2006. Experimental parameters affecting sensitivity and
To model estrogen receptor-ligand complexes, the coordinates
of the human ERa-ligand binding domain liganded with 17b-estra-
diol (1ERE), genistein (1X7R), and 4-hydroxytamoxifen (3ERT)
were taken from the Protein Databank. The three crystal structures
represent the active (17b-estradiol), the partially active (genistein),
and the inactive form (4-hydroxytamoxifen) of the estrogen recep-
tor (Brzozowski et al., 1997; Manas et al., 2004; Shiau et al., 1998).
Hydrogen atoms were added and charges from AMBER (Case et al.,
2005) were loaded. The default charge states of titratable sites on
the protein were chosen and all histidine residues were treated un-
charged. AM1 electrostatic potential (ESP) charges were calculated
for the ligands. All water molecules observed in the receptor crys-
tal structure were deleted with one exception: the conserved water
molecule bound to Glu53 and Arg394 was included. The estrogen
receptor structures were energy-minimized using a tethering con-
stant of 100 kcal/mol on the protein backbone atoms. Docking of
potential ligands was examined by program GOLD 3.2 using the
minimized structures of the estrogen receptor in the active as well
in the inactive conformation. All torsion angles in each ligand were
allowed to rotate freely. The binding site was defined on Phe404
with a radius of 15 Å. Gold scores were calculated using default
parameters in the programme and chosen as fitness function. The
fitness score is taken as the negative of the sum of the component
energy terms (protein–ligand hydrogen bond energy, protein–li-
gand van der Waals energy, ligand internal van der Waals energy,
ligand torsional strain energy), so that larger numerical fitness
indicate a better fitness in the model (Nissink et al., 2002; Verdonk
et al., 2003). For each molecule 10 docking runs were performed.
The resulting solutions were clustered on the basis of the heavy
atom rmsd values (1 Å). The top-ranked poses for each ligand were
retained and analyzed graphically within MOE 2008.10 (Chemical
Computing Group). To validate the results obtained by the auto-
mated docking procedure, a series of GRID calculations were per-
formed. Program GRID is an approach to predict non-covalent
interactions between a molecule of known three-dimensional
structure (i.e. estrogen receptor) and a small group as a probe (rep-
resenting chemical features of a ligand). The calculations were per-
formed using version 23 of the GRID program and the crystal
structures mentioned above. The calculations were performed on
a cube (13 ꢁ 15 ꢁ 12 Å) including the binding pocket in order to
search for binding sites complementary to the functional groups
of the ligands. Several probes were used to study the active site
of the estrogen receptor (hydroxyl, methyl and hydrophobic DRY
probe). The calculated GRID contour maps were then viewed
superimposed on the crystal structure of the estrogen receptor
using the MOE 2008.10 software.
specificity of
a yeast assay for estrogenic compounds: results of an
interlaboratory validation exercise. Anal. Bioanal. Chem. 386, 1419–1428.
Dinelli, G., Marotti, I., Bosi, S., Benedettelli, S., Ghiselli, L., Cortacero-Ramrez, S.,
Carrasco-Pancorbo, A., Segura-Carretero, A., Fernndez-Gutirrez, A., 2007. Lignan
profile in seeds of modern and old Italian soft wheat (Triticum aestivum L.)
cultivars as revealed by CE–MS analyses. Electrophoresis 28, 4212–4219.
Dixon, R.A., 2004. Phytoestrogens. Ann. Rev. Plant Biol. 55, 225–261.
Eklund, P., Riska, A., Sjoholm, R., 2002. Synthesis of R-(ꢀ)-imperanene from the
natural lignan hydroxymatairesinol. J. Org. Chem. 67, 7544–7546.
Kuhnle, G.G.C., Dell’Aquila, C., Aspinall, S.M., Runswick, S.A., Mulligan, A.A.,
Bingham, S.A., 2008. Phytoestrogen content of beverages, nuts, seeds, and oils.
J. Agric. Food Chem. 56, 7311–7315.
Larrosa, M., González-Sarrías, A., García-Conesa, M.T., Tomás-Barberán, F.A., Espín,
J.C., 2006. Urolithins, ellagic acid-derived metabolites produced by human
colonic microflora, exhibit estrogenic and antiestrogenic activities. J. Agric. Food
Chem. 54, 1611–1620.
Manas, E., Xu, Z., Unwalla, R., Somers, W., 2004. Understanding the selectivity of
genistein for human estrogen receptor-beta using X-ray crystallography and
computational methods. Structure 12, 2197–2207.
Mazur, W., Uehara, M., Wahala, K., Adlercreutz, H., 2000. Phyto-oestrogen content of
berries, and plasma concentrations and urinary excretion of enterolactone after
a single strawberry-meal in human subjects. Br. J. Nutr. 83, 381–387.
Mueller, S.O., Simon, S., Chae, K., Metzler, M., Korach, K.S., 2004. Phytoestrogens and
their human metabolites show distinct agonistic and antagonistic properties on
estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci. 80,
14–25.
Nissink, J.W., Murray, C., Hartshorn, M., Verdonk, M.L., Cole, J.C., Taylor, R., 2002. A
new test set for validating predictions of protein–ligand interaction. Proteins:
Struct., Funct., Genet. 49, 457–471.
Nurmi, T., Voutilainen, S., Nyyssönen, K., Adlercreutz, H., Salonen, J.T., 2003. Liquid
chromatography method for plant and mammalian lignans in human urine. J.
Chromatogr. B 798, 101–110.
Owens, W., Koëter, H.B.W.M., 2003. The OECD program to validate the rat
uterotrophic bioassay: an overview. Environ. Health Perspect. 111, 1527–1529.
Papadakis, E.N., Lazarou, D., Grougnet, R., Magiatis, P., Skaltsounis, A.L.,
Papadopoulou-Mourkidou, E., Papadopoulos, A.I., 2008. Effect of the form of
the sesame-based diet on the absorption of lignans. Br. J. Nutr. 100, 1213–1219.
Penalvo, J.L., Heinonen, S.M., Aura, A.M., Adlercreutz, H., 2005. Dietary sesamin is
converted to enterolactone in humans. J. Nutr. 135, 1056–1062.
Pike, A., Brzozowski, A., Hubbard, R., Bonn, T., Thorsell, A., Engstrom, O., Ljunggren,
J., Gustafsson, J., Carlquist, M., 1999. Structure of the ligand-binding domain of
oestrogen receptor beta in the presence of a partial agonist and a full antagonist.
EMBO J. 18, 4608–4618.
Pike, A., Brzozowski, A., Walton, J., Hubbard, R., Thorsell, A., Li, Y., Gustafsson, J.,
Carlquist, M., 2001. Structural insights into the mode of action of a pure
antiestrogen. Structure 9, 145–153.
Powell, E., Xu, W., 2008. Intermolecular interactions identify ligand-selective
activity of estrogen receptor alpha/beta dimers. Proc. Nat. Acad. Sci. USA 105,
19012–19017.